GlobeNewsWire
01 Oct 2026, 21:40 UTC · 5d ago
ChronoScale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue to $1 Billion and Sale of Ekso Bionics Business Unit
Impact · against what's priced in
The news is potentially a significant catalyst for CHRN, providing a concrete revenue target of $1 billion by Q3 2027 and simplifying the business model via the Ekso Bionics divestiture. However, because there is no established reconstruction of what the price currently assumes, the exact magnitude of the price impact cannot be determined.
- CHRN+0.60
No priced-in read yet




